Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Frontiers in OncologyOpen Access

Integrated single-cell and bulk RNA-seq analysis reveals prognostic stemness genes in leiomyosarcoma

View Full Paper
Ask AI
Bookmark
Share

Authors

ALAiju LouYCYu‐Dong CaiTZTianqi Zheng

Discussion

Loading...

Member takes

Overview

Integrated RNA sequencing analysis uncovers prognostic stemness markers in leiomyosarcoma, indicating potential therapeutic targets.

Key Points

  • Cells with a high stemness index displayed a more complex tumor immune microenvironment, suggesting significant implications for survival outcomes.
  • Differential expression analysis pinpointed six key prognostic markers associated with tumor cell proliferation in leiomyosarcoma.
  • The study utilized an integrated approach combining single-cell and bulk RNA sequencing data for comprehensive analysis.
  • Identifying these markers offers new insights into the molecular mechanisms of leiomyosarcoma, aiding in personalized treatment strategies.

Cite This Study

Lou et al. (2025) studied this question.

synapsesocial.com/papers/68c23a2cb210217d6477f200https://doi.org/10.3389/fonc.2025.1604413
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integration of single-cell and bulk RNA sequencing to identify unique tumor stem cells and construct novel prognostic markers for assessing ESCA prognosis and drug sensitivity2025
  2. 2Identification and comprehensive analysis of an immune-related gene prognostic model for indicating tumor immune microenvironment features in soft tissue sarcoma2025
  3. 3Targeting Pan-Cancer Stemness: Core Regulatory lncRNAs as Novel Therapeutic Vulnerabilities2025
  4. 4Construction of a glycosylation-related prognostic signature for predicting prognosis, tumor microenvironment, and immune response in soft tissue sarcoma2025
  5. 5Identification of the Immune Microenvironment, Mutation Burden, Immunotherapy, and Drug Sensitivity Related to Lung Adenocarcinoma Tumor Stem Cells via WGCNA2025